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Abstract
Background: An estimated 15,000 children and adolescents under the age of 19 years are diagnosed with leukemia,
lymphoma and other tumors in the USA every year. All children and adolescent acute leukemia patients will undergo
chemotherapy as part of their treatment regimen. Fortunately, survival rates for most pediatric cancers have improved
at a remarkable pace over the past three decades, and the overall survival rate is greater than 90 % today. However,
significant differences in survival rate have been found in different age groups (94 % in 1–9.99 years, 82 % in ≥10 years
and 76 % in ≥15 years). ALL accounts for about three out of four cases of childhood leukemia. Intensive chemotherapy
treatment coupled with prophylactic or therapeutic antibiotic use could potentially have a long-term effect on the
resident gastrointestinal (GI) microbiome. The composition of GI microbiome and its changes upon chemotherapy in
pediatric and adolescent leukemia patients is poorly understood. In this study, using 16S rRNA marker gene sequences
we profile the GI microbial communities of pediatric and adolescent acute leukemia patients before and after
chemotherapy treatment and compare with the microbiota of their healthy siblings.
Results: Our study cohort consisted of 51 participants, made up of matched pediatric and adolescent patients
with ALL and a healthy sibling. We elucidated and compared the GI microbiota profiles of patients and their
healthy sibling controls via analysis of 16S rRNA gene sequencing data. We assessed the GI microbiota
composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing
stool samples taken before chemotherapy with stool samples collected at varying time points during the
chemotherapeutic treatment. The microbiota profiles of both patients and control sibling groups are dominated
by members of Bacteroides, Prevotella, and Faecalibacterium. At the genus level, both groups share many taxa in
common, but the microbiota diversity of the patient group is significantly lower than that of the control group.
It was possible to distinguish between the patient and control groups based on their microbiota profiles. The top
taxa include Anaerostipes, Coprococcus, Roseburia, and Ruminococcus2 with relatively higher abundance in the
control group. The observed microbiota changes are likely the result of several factors including a direct influence
of therapeutic compounds on the gut flora and an indirect effect of chemotherapy on the immune system, which, in
turn, affects the microbiota.
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Conclusions: This study provides significant information on GI microbiota populations in immunocompromised
children and opens up the potential for developing novel diagnostics based on stool tests and therapies to improve
the dysbiotic condition of the microbiota at the time of diagnosis and in the earliest stages of chemotherapy.
Keywords: Pediatric leukemia, Gastrointestinal microbiota, 16S rRNA gene sequencing, rRNA, Ribosomal RNA
Background
Acute lymphoblastic leukemia (ALL) is a malignant disease
of the bone marrow in which early lymphoid precursors
proliferate and replace the normal hematopoietic cells of
the marrow [1]. The lymphoid progenitor cells in patients
with ALL are affected by the disease, leading to an im-
paired immune system typically observed at the time of
diagnosis. ALL is the most common type of leukemia in
children in the United States accounting for 26 % of all
cancers in children up to 14 years of age and for 75 % of all
pediatric leukemia cases [2]. All children and adolescents
diagnosed with ALL will undergo chemotherapy as part of
their treatment plan, and their health can be severely com-
promised due to the treatment with chemotherapeutic
drugs. Chemotherapy can damage healthy cells in the lin-
ing of the digestive system and gastrointestinal (GI) distur-
bances are often induced in response to chemotherapy.
Chemotherapeutic and antibiotic treatment has a detri-
mental impact on the host microbial ecosystem, which is
essential for host mucosal protection [3]. The cytotoxic ef-
fects of these treatments lead to additional immunosup-
pression, which entails episodes of febrile neutropenia and
potentially life-threatening bloodstream infections. Further,
use of prophylactic and therapeutic antibiotics disrupts the
GI microbiome’s ecological balance [4]. Medium-term
gastrointestinal health outcomes of chemotherapy and
disruptions of the intestinal microbial ecology include
vomiting, diarrhea, constipation and Clostridium difficile
infection-associated diarrhea (CDAD). To varying degrees,
survivors of children and adolescents treated for cancer
experience a range of long-term growth and developmen-
tal, organ function, fertility and reproduction and psycho-
logical adverse outcomes. The growing population of
survivors of pediatric cancer reflects a highly vulnerable
group of individuals who will probably experience adverse
health-related and quality-of-life outcomes during their
subsequent lifetimes, as a result of their curative cancer
treatment [5–8]. There is increasing evidence that the
composition of the GI microbiome may affect, and is
modulated by, the human immune system [9]. Perturbed
GI microbiomes have been associated with decreased
immune competence, detrimental metabolic changes
(e.g. obesity and malnutrition), susceptibility to GI infec-
tions and inflammatory syndromes [10, 11]. Likewise, sev-
eral microbiome studies have examined the impact of
antibiotics on the microbiota of individuals using 16S
rRNA gene sequencing alone [12–16] or combined with
metatranscriptomics [17]. These studies have demon-
strated that administration of antibiotics can perturb this
microflora temporarily and in certain cases permanently.
Antibiotic-mediated alteration of the gut microbiome can
converts the global metabolic profile to one that favors C.
difficile germination and growth [18]. Furthermore, che-
motherapeutics have a detrimental effect on the intestinal
microbial composition, coinciding in time with the de-
velopment of chemotherapy-induced mucositis [19].
There is, however, a limited understanding of the GI
microbiome composition of pediatric and adolescent
leukemia patients and the impact, if any, of contempor-
ary chemotherapeutic treatments. The rationale for this
study is to define and compare the GI microbiota compos-
ition of pediatric and adolescent leukemia patients with
their healthy sibling controls via analysis of high-
throughput sequencing data. And also, to assess the
changes in microbiota structure of pediatric and adoles-
cent leukemia patients during chemotherapy by compar-
ing the samples taken before and after chemotherapy at
varying time points during the chemotherapeutic treat-
ment. Our results provide significant information on GI
microbiota composition in immunocompromised children
and indicate that the baseline microbiota of immunocom-
promised children was substantially different from their
healthy siblings. It creates the potential for the better
management of GI and systemic complications associated
with immunodeficiency and other disease conditions of
this type. Furthermore, characterizing the GI microbiota
dynamics following chemotherapy treatment will address
what alterations happen to the GI microbiota during and




A cohort study was designed to assess the impact of
chemotherapy on the GI microbiota of pediatric and
adolescent patients diagnosed with acute B-cell leukemia.
The study cohort consisted of 51 participants, made up of
23 matched patients and a healthy sibling and five un-
matched patients. Five patients who did not have enrolled
healthy siblings were also included in the cohort. Three
subjects not complete the study: two withdrew and one
subject was deceased. Subject demographics by age and
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gender are shown in Table 1. All study participants were
enrolled in the Hyundai Cancer Institute, Children’s Hos-
pital Orange County (CHOC Children’s), California, USA.
Human subject protocol and consent forms were estab-
lished, and approved by the Institutional Review Boards at
CHOC Children’s and the J. Craig Venter Institute (JCVI).
Stool samples were collected at the completion of each
treatment stage during the patient's stay at the hospital,
referred to as “sampling visits”. Samples marked “visit 1”
were collected at the time of diagnosis before any chemo-
therapy was administered, and thus provided baseline
microbiota for each patient. As such, patient’s samples
were collected before chemotherapy, during induction
chemotherapy (chemotherapy given to induce a remis-
sion), consolidation chemotherapy (chemotherapy given
once a remission is achieved) and during maintenance
therapy (chemotherapy given in lower doses to assist in
prolonging a remission). All healthy sibling controls
were sampled once, aligning with the time period be-
fore chemotherapy began on the patient (Additional file
1: Table S1), however, four siblings samples were col-
lected at two time points, which were excluded from the
analysis. All patients with ALL enrolled in the study re-
ceived antibiotic prophylaxis with sulfamethoxazole and
trimethoprim during treatment and steroid prophylaxis at
the induction stage. Incidental use of antibiotics and oc-
currence of infections in the month before each visit were
recorded. Additional file 1: Table S1 provides details of the
sampling visits for each patient over the period of
enrollment.
Sample collection
Samples were collected using the Human Microbiome
Project (HMP) collection protocol section 7.3.3. with no
modifications. Stool specimens were collected and trans-
ported to CHOC Children’s for deoxyribonucleic acid
(DNA) extraction [20].
DNA extraction
Bacterial DNA was extracted from the stool samples
using the PowerSoil® DNA Isolation Kit from MO BIO
Laboratories, Inc. (catalog no: 12888) and by using the
protocol as described in Yooseph et al., [21].
Library construction and sequencing
DNA was amplified using primers that targeted the V1-V3
regions of the 16S rRNA gene [22]. These primers in-
cluded the i5 and i7 adaptor sequences for Illumina MiSeq
sequencing as well as unique 8 bp indices incorporated
onto both primers such that each sample received its own
unique barcode pair. This method of incorporating the
adaptors and index sequences onto the primers at the
polymerase chain reaction (PCR) stage provided minimal
loss of sequence data when compared to previous library
construction methods that would ligate the adaptors to
every amplicon after amplification. This method also al-
lows generating sequence reads which were all in the same
5′-3′ orientation. Using approximately 100 ng of extracted
DNA, the amplicons were generated with Platinum Taq
polymerase (ThermoFisher, catalog no: 11304-011) and by
using the following cycling conditions: 95 °C for 5 min for
an initial denaturing step followed by 95 °C for 30 s, 55 °C
for 30 s, 72 °C for 30 s for a total of 35 cycles followed by
a final extension step of 72 °C for 7 min then stored at 4 °
C. Once the PCR for each sample was completed, the
amplicons were purified using the QIAquick PCR purifi-
cation kit (QIAGEN, catalog no: 28104), quantified using
Tecan fluorometric methods (Tecan Group, Männedorf,
Switzerland), normalized, and then pooled in preparation
for cluster generation followed by Illumina MiSeq se-
quencing using the dual index 2x300 bp format (Roche,
Branford, CT) following the manufacturer’s protocol.
16S rRNA sequence data processing
After primer trimming, the paired-end reads were quality
trimmed using the DynamicTrim program (available in
the SolexaQA suite [23]). Subsequently, mothur (v.1.34.4)
[24] was used to merge overlapping forward and reverse
reads to generate contig sequences from the paired-end
reads. Chimeric sequences were identified using the
UCHIME [25] implementation in mothur; these se-
quences were removed from the downstream analysis.
The resulting sequence set was clustered at different se-
quence identity thresholds (90, 95 and 97 %) using CD-
HIT [26] to generate Operational Taxonomic Units
(OTUs); OTU representatives were assigned taxonomy
using the mothur implementation of the Ribosomal Data-
base Project (RDP) Classifier [27]. While the RDP
Table 1 Characteristics of study subjects
Diagnosis Acute lymphocytic leukemia (total n = 28)
Age group Ages 0–14 (n = 21) Ages 15–19 (n = 4) Ages 20–23 (n = 3)
Gender Male: 13 (62 %) Male: 4 (100 %) Male: 2 (67 %)
Female: 8 (38 %) Female: 0 (0 %) Female: 1 (33 %)
Sibling Healthy control (total n = 23) Ages 2–25 years (median age 9.3 years)
Gender Male: 7 (30 %), Female: 16 (70 %)
Three participants in the 20–23 years age group did not complete the study. Two withdrew, and one was deceased
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classifier has a goal of generating genus-level taxo-
nomic assignments, not all sequences could, however, be
confidently assigned taxonomy to the genus level (using
the bootstrap confidence threshold of 80 %); we denote
these sequences by appending the tag unclassified to the
end of their taxonomic assignment (one of phylum, class,
order, or family levels).
Electronic medical records
Study-specific participant data was collected at each speci-
men collection time point. Also, multiple time-stamped
data points on each participant starting from the initial
visit were gathered in the electronic medical record
(EMR) at CHOC Children’s. Events recorded in the EMR
were obtained for each patient identified by anonymized
participant identification numbers.
16S rRNA data analysis
The Shannon diversity index was calculated from the
OTUs in the samples to assess the alpha diversity of the
microbial communities they represent. This was done
using mothur [24]. Calculations were performed on sub-
sampled sequences to account for differences in sequen-
cing depth across the samples. To test whether the
microbiota diversity difference between the patients and
controls was statistically significant, we applied the Wil-
coxon Rank Sum test in R, the statistical programming
language, [28] to calculate the p-value for the comparison.
The mean age difference between patient and control
groups was evaluated using the t-test. For the average
microbiota diversity between different time points, we
used a paired (one sample) t-test.
The signature associated with the patient and control
groups were identified using Random Forests (RF) [29], as
implemented in the RF package (version 4.6–10) that is
available in the R programming language and environ-
ment for statistical computing (version 3.2.2) [28]. For this
analysis, OTUs (at 97 % identity threshold) with the same
taxonomic classification were combined into a single bin,
thereby generating a set of taxon bins where each bin had
a unique taxonomy; we note here that the best taxonomic
resolution for a taxon bin is at the genus level and that
some of the bins may have less resolved taxonomy (that is,
at one of phylum, class, order, or family levels). The se-
quence counts in these taxon bins were used to calculate
their relative abundance in each sample, and these abun-
dances were used as input features for the RF analysis.
Gender, antibiotic use, and alpha diversity (Shannon
index) were also included as input features.
Results and discussion
Cohort description
The patient cohort included 28 children and adolescent
participants with ALL, age 3–23 years (median age
9.9 years), and consisted of 19 male and nine female
members. Similarly, the control cohort included 23 sib-
ling controls age 2–25 years (median age 9.3 years) with
16 females and seven males (Table 1). The patient cohort
showed a high prevalence of ALL in males; it has been
demonstrated previously that childhood cancer occurs
more frequently in males than in females [30]. The mean
age difference between patient and control groups was not
statistically significant based on a t-test. A total of 180
fecal samples were collected and used over a period of
one year for 16S rRNA sequencing and analysis (Add-
itional file 1: Table S1). There were an average 16,270 an-
notated sequences per sample, (82,969 – maximum, and
10,498 – median). Four patients were positive for C. diffi-
cile. The low incidence of C. difficile in this immunocom-
promised patient population may reflect the efficiency of
antibiotic prophylaxis and other mitigation strategies
employed by the clinical care team.
GI microbiota composition
The microbiota profiles (Visit 1) of both patient and
control groups were dominated by members of the gen-
era Bacteroides, Prevotella, and Faecalibacterium, with
these having mean abundances of 62.2, 7.3, and 6.4 % re-
spectively, in the patient group, and 40.2, 12.2, and 8.3 %
respectively, in the control group. The rank orders of
the remaining lower abundant taxa were different in the
two groups (Fig. 1). However, at the genus level, both
patient and control groups share many taxa in common
(Fig. 1).
The OTUs identified from the samples were used to
compute the alpha diversity of the microbial communi-
ties (using the Shannon index). These calculations reveal
the microbiota diversity (using OTUs at 97 % identity
threshold) of the Patient group (Visit 1) to be lower than
that of the Control group (Visit 1), with this difference
being statistically significant (p-value 0.0012, Wilcoxon
Rank Sum test) (Fig. 2). The Patient group was further
partitioned into those who reported taking antibiotics in
the one month period prior to Visit 1 (Patient_A group)
and those who did not take antibiotics in this period
(Patient_NA group). The microbiota diversity in each of
these groups was compared with that of the Control
group, and also found to be different using the Wilcoxon
Rank Sum test (p-value for Control vs. Patient_A:
0.0027; p-value for Control vs. Patient_NA: 0.028). These
observations also hold for diversity calculations based on
OTUs generated using 95 and 90 % identity thresholds
as well (Additional file 2: Figure S1).
It was possible to distinguish between the patient and
control groups (Visit 1) based on their microbiota pro-
files. For this assessment, we used RF to identify features
that could discriminate between the two groups. We ob-
served a high classification accuracy, as measured by
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Area Under the Curve (AUC), of 87.9 % (Fig. 3). The input
features (taxon abundances and sample metadata) were
ranked by order of their importance in the classification
(using their MeanDecreaseGini value). Based on this, the
top taxa include Anaerostipes, Coprococcus, Roseburia,
and Ruminococcus2 (all of these being in higher relative
abundance in the Control group), while metadata on anti-
biotic use and alpha diversity are also important.
The protective role of commensal intestinal bacteria in
human disease is increasingly being appreciated. How-
ever, microbiome studies that investigate the role of
bacteria in human disease have focused primarily on in-
flammatory bowel disease, which is caused by a chronic
inflammatory process. Previous studies have shown that
the intestinal microbiota in patients with inflammatory
bowel disease (IBD) is characterized by a contraction of
Firmicutes and Bacteroidetes and an expansion of Pro-
teobacteria [31]. Lachnospiraceae (which comprises the
Clostridium XIVa and IV groups within the order Clos-
tridiales) and Roseburia (butyrate-producing bacterium)
were greatly reduced, in acute leukemia patients com-
pared to a healthy sibling (Fig. 1), but the Bacteroides
are increased in patients compare to sibling controls.
Bacteria producing butyrate play a major role in the
composition of the mucus layer, as butyrate is an import-
ant energy source for intestinal epithelial cells and plays a
role in the maintenance of colonic homeostasis [32]. Sev-
eral intestinal bacteria produce short chain fatty acids
(SCFAs), with butyrate being the most thoroughly investi-
gated. Butyrate is produced by F. prausnitzii and Clostrid-
ium XIVa and has been shown to have profound anti-
inflammatory effects [32–36]. The observed reduction in
Lachnospiraceae and Roseburia in acute leukemia patients
may increase the risk of developing chemotherapy in-











































Fig. 1 Mean microbial taxon abundances in the Patient and Control groups (Visit 1). 16S ribosomal RNA gene surveys in the stool samples are
used to taxonomically identify the gut microbiota
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Microbiota diversity changes during chemotherapy and
maintenance therapy
We assessed the changes in microbiota diversity for the
patients after chemotherapy (using OTUs calculated at
97 % identity threshold). As part of this, we evaluated
differences in diversity for three cases: (a) diversity at
Visit 2 (after chemotherapy) versus diversity at Visit 1
(before chemotherapy), (b) diversity at the final visit ver-
sus diversity at Visit 1, and (c) the average diversity for
visits after Visit 1 versus diversity at Visit 1. For each of
these comparisons, we used a paired (one sample) t-test to
assess whether the difference in diversity was 0 or greater
than 0. As shown in Fig. 4, while the diversity increase
was not significant for case (a) with a p-value of 0.318, the
increase for subsequent visits were significant, with p-
values of 0.00026 and 0.00643 for cases (b) and (c)
respectively.
It is likely that these observed changes in the GI
microbiota diversity during therapy are the result of sev-
eral factors including a direct influence of some of the
therapeutic compounds or combination of chemother-
apy and steroid prophylaxis on the gut flora, an indirect
effect of chemotherapy on the immune system, which, in
turn, affects the microbiome, or dietary choices during
therapy. The lymphoid progenitor cells in ALL patients
are affected during the disease, leading to the impaired
immune system typically observed at the time of diagno-
sis [21, 37]. It is known that microbiome community
structure is determined by both host and environmental
factors [38]. If any one of these factors is greatly per-
turbed, a drastic composition shift in the composition of
the microbiome can be expected.
Conclusions
Several microbiome studies have demonstrated that
administration of antibiotics can perturb this micro-
flora temporarily and in particular cases permanently
[12–15, 39]. Antibiotic-induced shifts can increase sus-
ceptibility to C. difficile infection [18]. Similarly, muco-
sal barrier injury, characterized by both inflammation
and cell loss in the epithelial barrier lining of the
gastrointestinal tract, is one of the most debilitating
side effects of radiotherapy and chemotherapy treat-
ment [39, 40]. However, the composition of GI










Fig. 2 Box-plots of the alpha diversity (based on OTUs at 97 % indentity threshold) of the Control and Patient groups. The Patient group is further
partitioned into the group taking antibiotics 1-month period Visit 1 (Patient_A) and the group not taking antibiotics (Patient_NA). The Y-axis denotes
alpha diversity (Shannon Index values). The mean alpha-diversity values for the various groups are 3.92 (Control), 3.07 (Patient), 2.96 (Patient_A), and
3.25 (Patient_NA). The Patient group has a lower microbiota diversity (statistically significant) compared to the Control group (p-value = 0.0012).
The diversities of the Patient_A and Patient_NA groups are also significantly lower (p-value < 0.05) than the Control group
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microbiota in pediatric and adolescent leukemia pa-
tients and the microbiota changes after contemporary
chemotherapy has not been investigated. Our study is
the first, to the best of our knowledge, to address a
population of pediatric and adolescent patients with
acute leukemia and to compare these patients with
their sibling controls. This characterization of the GI
microbiota in pediatric and adolescent patients with
acute leukemia has provided significant information on
GI microbiota populations in immunocompromised
individuals and opens up the potential for developing
novel diagnostics based on stool tests as well as devel-
oping therapies to improve the dysbiotic condition of
the microbiota at the time of diagnosis and in the
earliest stages of chemotherapy. This creates the po-
tential for the better management of GI and systemic
complications associated with immunodeficiency and
other disease conditions of this type. Furthermore,
characterizing the GI microbiota dynamics and im-
mune response following chemotherapy treatment will
a
b
Fig. 3 Random Forest analysis to distinguish between Patient and Control groups based on microbiota profiles (and sample metadata). The top
figure Receiver Operating Characteristic (ROC) plot (a) shows the classification accuracy (as evaluated by AUC) while the bottom figure (b) lists the
input features in decreasing order of importance (based on MeanDecreaseGini values)
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address what alterations happen to the GI microbiota
during and following chemotherapy regimens and may
be correlated with response to treatment. We antici-
pate expanding this study to get more detailed infor-
mation on microbial profiles that are associated with
or that lead to the development of various infections
including C. difficile and persistent diarrhea. Further,
we may find that the composition of the microbiota
may ultimately be used as an indicator as to how well
a patient may respond to different chemotherapy
treatments.
Additional files
Additional file 1: Table S1. List of fecal samples collected for each
patient over the period of enrollment for 16S rRNA gene sequencing and
analysis. (XLSX 17 kb)
Additional file 2: Figure S1. Box-plots of the alpha diversity of OTUs at
95 % and 90 % identity threshold of the Control and Patient groups. The
Patient group is further partitioned into the group taking antibiotics 1-
month period Visit 1 (Patient_A) and the group not taking antibiotics
(Patient_NA). (A) Alpha diversity for 95 % OTUs, the Y-axis denotes alpha
diversity (Shannon Index values). The Wilcoxon Rank Sum test p-value =
0.00253 for Control vs Patient, p-value = 0.00328 for Control vs Patient_A
and p-value = 0.05969 for Control vs Patient_NA. (B) Alpha diversity for
90 % OTUs, the Y-axis denotes alpha diversity (Shannon Index values). The
Wilcoxon Rank Sum test p-value = 0.00156 for Control vs Patient, p-value =
0.00328 for Control vs Patient_A and p-value = 0.03119 for Control vs
Patient_NA. In both cases (A, B) the Patient group has a lower microbiota
diversity (statistically significant) compared to the Control group (p-value <
0.0026). The diversities of the Patient_A and Patient_NA groups are also
significantly lower (p-value < 0.05) than the Control group. (PDF 203 kb)
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